Recent investigations have focused on the convergence of GLP-1|GIP|glucagon receptor stimulant therapies and dopamine neurotransmission. While GCGR activators are increasingly employed for managing type 2 T2DM, their potential effects on reinforcement circuits, specifically governed by dopaminergic networks, are attracting considerable focus. This